Provided by Tiger Fintech (Singapore) Pte. Ltd.

Orchestra BioMed

3.31
+0.26008.52%
Post-market: 3.310.00000.00%16:04 EDT
Volume:289.99K
Turnover:944.61K
Market Cap:126.81M
PE:-1.87
High:3.35
Open:3.10
Low:3.06
Close:3.05
Loading ...

B. Riley Cuts Price Target on Orchestra BioMed Holdings to $12 From $15, Keeps Buy Rating

MT Newswires Live
·
30 May

Promising Innovations and Strategic Advancements Drive Buy Rating for Orchestra BioMed Holdings

TIPRANKS
·
17 May

Orchestra BioMed Holdings Is Maintained at Buy by Chardan Capital

Dow Jones
·
14 May

Orchestra BioMed Hldgs Q1 EPS $(0.49) Misses $(0.48) Estimate, Sales $868.00K Beat $575.80K Estimate

Benzinga
·
13 May

Orchestra BioMed reports Q1 EPS (49c), consensus (48c)

TIPRANKS
·
13 May

Orchestra BioMed Holdings Reports Q1 2025 Revenue Increase to $0.9M, Net Loss Widens to $18.8M, EPS at $0.49 Loss

Reuters
·
13 May

Orchestra Biomed Q1 EPS USD -0.49 VS. Ibes Estimate USD -0.48

THOMSON REUTERS
·
13 May

Press Release: Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

Dow Jones
·
13 May

Orchestra BioMed Holdings Is Maintained at Overweight by Barclays

Dow Jones
·
06 May

Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks
·
05 May

Major Shareholder Boosts Investment in Orchestra BioMed Holdings!

TIPRANKS
·
30 Apr

Orchestra BioMed Receives US FDA Approval for Heart Device Trial

MT Newswires Live
·
30 Apr

BRIEF-Orchestra Biomed Receives FDA Approval Of Ide To Initiate U.S. Coronary Pivotal Trial Randomizing First-In-Class Sirolimus-Angioinfusion Balloon, Virtue Sab, Head-To-Head With Paclitaxel-Coated Balloon

Reuters
·
29 Apr

Orchestra Biomed Holdings Inc: Targeting Initiation of Virtue Trial During Second Half of 2025

THOMSON REUTERS
·
29 Apr

Orchestra Biomed Receives FDA Approval of Ide to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-Angioinfusion Balloon, Virtue SAB, Head-to-Head With Paclitaxel-Coated Balloon

THOMSON REUTERS
·
29 Apr

Orchestra BioMed Holdings: Buy Rating Affirmed on Breakthrough Device Designation and Promising AVIM Therapy Developments

TIPRANKS
·
24 Apr

Orchestra BioMed granted breakthrough device designation, says H.C. Wainwright

TIPRANKS
·
24 Apr

Orchestra BioMed Holdings Is Maintained at Buy by Chardan Capital

Dow Jones
·
23 Apr

Orchestra BioMed Says AVIM Therapy Gets US FDA Breakthrough Device Designation

MT Newswires Live
·
22 Apr

Orchestra Biomed Holdings Shares up 9% on FDA's Fast Track Tag for Blood Pressure Therapy

THOMSON REUTERS
·
22 Apr